Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.78 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.78 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.78 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105167 | 1.00 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2107862 | 0.89 | F11 (1.00) | F11KLKB1 | |
| SCHEMBL2332723 | 0.88 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2105118 | 0.87 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2105120 | 0.87 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL4786853 | 0.85 | F11 (0.75) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL3176860 | 0.82 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2107197 | 0.81 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2107198 | 0.81 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL5270842 | 0.81 | F11 (0.92) | F11KLKB1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | claimed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | claimed |
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| EP-1966141-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | F11 2/4885KLKB1 18/4885PRSS1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.